Bahija Jallal talks about the experience Immunocore has gained commercializing KIMMTRAK since its 2022 approval and into what areas she hopes to expand the company's development.

Chris Gibson describes the new technologies that are accelerating and refining drug development, shares best practices, and elaborates on Recursion's partnerships.

Yvonne Greenstreet talks about how Alnylam has been moving RNAi beyond the liver and previews the year ahead, including HELIOS-B.

Vipin Garg explains the theory of how GLP-1 cause weight loss and gives the rationale for adding glucagon agonism for added effect.

Ken Keller describes recent advances in ADC technology, talks about the recent Merck deal, and what it was like to change breast cancer at ASCO in 2022.

Harvey Berger describes the science of ferroptosis and his experience working with Kojin's scientific founder Stuart Schreiber. He also shares a few memories of the beginnings of the biotech sector.

Bobby Azamian provides an update on the commercial launch of XDEMY in demodex blepharitis, and discusses programs for meibomian gland disease, rosacea, and Lyme disease.

Trevor Martin describes how Mammoth is working on the evolution of CRISPR to help make it more versatile for potential use in broad in-vivo applications.